Introduction Singapore, 5 May 2026: Hongene Biotech Corporation today announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end...
Introduction In Singapore, January 12, 2026; Hongene Biotech announced the receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for use in mRNA...
Introduction SINGAPORE (July 10th, 2025) – Hongene Biotech Corporation, a contract development and manufacturing organization (CDMO) specializing in nucleic acid therapeutics, today announced its critical role in advancing DNV001, a...
Hongene launches operations at its new mRNA CDMO GMP facility, ensuring efficient, high-quality production of mRNA therapeutics and vaccines. The new facility consists of more than 30,000 sq. ft. of...
SAN DIEGO, Calif., April 24, 2024 (BUSINESS WIRE), Hongene Biotech Corporation, a global specialist in nucleic acid raw material supply and CDMO services, and n-Lorem, a nonprofit foundation formed a new partnership to support...
NEWS Recently, at Hongene Biotech's high-tech GMP facility, Hongene Biotech and Syensqo officially signed a strategic cooperation framework agreement. This milestone event signifies that both parties will engage in deeper...
NEWS On September 9, 2024, ReciBioPharm, a US-based contract development and manufacturing organization (CDMO) service provider, and Hongene Biotech, a leading supplier in the nucleic acid raw materials field, announced...